Eupraxia Pharmaceuticals (EPRX) said Tuesday data from its ongoing trial evaluating EP-104GI for eosinophilic esophagitis treatment showed 59% of patients achieved clinical remission at 12 weeks.
At 24 weeks, 76% of the patients maintained clinical remission, Eupraxia said.
No serious adverse events have been reported, and the drug continues to be well tolerated at all dose levels by patients, the company said.
Eupraxia said that top-line data from the phase 2b portion of the trial is expected in Q3.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments